Market Definition Key in NxStage/Fresenius Merger Review

Market definition will be key in Germany-based Fresenius Medical Care’s $2 billion deal to acquire US-headquartered NxStage Medical, antitrustfeatured

Bayer Agreement with BASF Does Not Answer All EC Antitrust Issues

Last week BASF agreed to acquire significant parts of Bayer’s seed and non-selective herbicide businesses for $7 billion, but the deal does not answer all offeatured

CADE to Clear Time Warner/AT&T with Behavioral Remedies

Updated at 12:11pm EDT – The tribunal of Brazilian regulator CADE will approve the ongoing merger between AT&T and Time Warner with behavioralfeatured

Time Warner/AT&T Focus on Timing

With additional reporting by Valeria Camerino – An attorney for a public interest group that had sought to intervene in the Department of Justice’s review of thefeatured

Monsanto/Bayer Early Remedy Package Not Expected at European Commission

As the European Commission’s review of Bayer’s acquisition of Monsanto proceeds, Bayer is not planning to proactively offer remedies to the commission beyond thosefeatured

Monsanto and Bayer in Remedy Discussions with Indian Regulator

Monsanto and Bayer are in pre-phase 2 remedy negotiations with the Competition Commission of India, several antitrust sources familiarfeatured

Australian Regulators Deferring to Europe and US in Monsanto/Bayer Deal

Australia’s competition regulator is taking a similar approach in reviewing and how it will ultimately decide on Bayer AG’s $66 billion acquisition of Monsantofeatured

360b /

Luxottica/Essilor Update on Australia and Other Jurisdictions

Australian antitrust regulator, the Australian Competition and Consumer Commission, will look at both the horizontal and vertical effects of the proposed merger between Italian eyewearfeatured

DOJ “Dropped the Ball” on Parker Hannifin Review

The Department of Justice’s civil antitrust lawsuit against Parker Hannifin, challenging its completed acquisition of CLARCOR is extraordinary, several antitrust attorneysfeatured

Monsanto/Bayer Expected to Receive Statement of Objections from European Commission

Bayer is expected to receive a statement of objections from the European Commission as the regulator works through its phase II review of Bayer’s acquisition of Monsanto, severalfeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.